D
Delphine Rea
Researcher at University of Paris
Publications - 261
Citations - 14581
Delphine Rea is an academic researcher from University of Paris. The author has contributed to research in topics: Imatinib mesylate & Nilotinib. The author has an hindex of 51, co-authored 228 publications receiving 12182 citations. Previous affiliations of Delphine Rea include Paris Diderot University & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon,Delphine Rea,Joelle Guilhot,François Guilhot,Françoise Huguet,Franck E. Nicolini,Laurence Legros,Aude Charbonnier,Agnès Guerci,Bruno Varet,Gabriel Etienne,Josy Reiffers,Philippe Rousselot +12 more
TL;DR: Imatinib discontinuation in this setting yields promising results for molecular relapse-free survival, raising the possibility that, at least in some patients, CML might be cured with tyrosine kinase inhibitors.
Journal ArticleDOI
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
Jorge E. Cortes,Dong-Kee Kim,Javier Pinilla-Ibarz,P. le Coutre,Ronald Paquette,Charles Chuah,F. E. Nicolini,Jane F. Apperley,Hanna Jean Khoury,Moshe Talpaz,John F. DiPersio,Daniel J. DeAngelo,Elisabetta Abruzzese,Delphine Rea,Michele Baccarani,Martin C. Müller,Carlo Gambacorti-Passerini,Stephane Wong,Stephanie Lustgarten,Victor M. Rivera,Timothy P. Clackson,Christopher D. Turner,Frank G. Haluska,François Guilhot,Michael W. Deininger,Andreas Hochhaus,Timothy P. Hughes,J. M. Goldman,Neil P. Shah,Hagop M. Kantarjian +29 more
TL;DR: Ponatinib had significant antileukemic activity across categories of disease stage and mutation status and were durable; the estimated rate of a sustained major cytogenetic response of at least 12 months was 91%.
Journal ArticleDOI
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Andreas Hochhaus,Michele Baccarani,Richard T. Silver,Charles A. Schiffer,Jane F. Apperley,Francisco Cervantes,Richard E. Clark,Jorge E. Cortes,Michael W. Deininger,François Guilhot,Henrik Hjorth-Hansen,Timothy P. Hughes,Jeroen Janssen,Hagop M. Kantarjian,Dong-Wook Kim,Richard A. Larson,Jeffrey H. Lipton,Francois-Xavier Mahon,Jiří Mayer,Franck E. Nicolini,Dietger Niederwieser,Fabrizio Pane,Jerald P. Radich,Delphine Rea,Johan Richter,Gianantonio Rosti,Philippe Rousselot,Giuseppe Saglio,Susanne Saußele,Simona Soverini,Juan Luis Steegmann,Anna G. Turkina,Andrey Zaritskey,Ruediger Hehlmann +33 more
TL;DR: An expert panel to critically evaluate and update the evidence to achieve goals to achieve a stable deep molecular response (DMR) and discontinuing medication for treatment-free remission (TFR) in chronic myeloid leukemia.
Journal ArticleDOI
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years
Philippe Rousselot,Françoise Huguet,Delphine Rea,Laurence Legros,Jean Michel Cayuela,Odile Maarek,Odile Blanchet,Gerald Marit,Eliane Gluckman,Josy Reiffers,Martine Gardembas,Francois-Xavier Mahon +11 more
TL;DR: It is hypothesized that relapses observed within 6 months reflect the kinetics of undetectable dividing chronic myelogenous leukemia (CML) cells, which may be eradicated or controlled in long-term nonrelapsing patients, as described in the study.
Journal ArticleDOI
Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia
Neil P. Shah,Hagop M. Kantarjian,Dong-Wook Kim,Delphine Rea,Pedro Enrique Dorlhiac-Llacer,Jorge Milone,Jorge Vela-Ojeda,Richard T. Silver,H. Jean Khoury,Aude Charbonnier,Nina Khoroshko,Ronald Paquette,Michael W. Deininger,Robert H. Collins,Irma Otero,Timothy P. Hughes,Eric Bleickardt,Lewis C. Strauss,Stephen S. Francis,Andreas Hochhaus +19 more
TL;DR: Dasatinib 100 mg once daily retains the efficacy of 70 mg twice daily with less toxicity, and intermittent target inhibition with tyrosine kinase inhibitors may preserve efficacy and reduce adverse events.